Acumen Pharmaceuticals (ABOS) Accounts Payables (2020 - 2026)

Acumen Pharmaceuticals' Accounts Payables history runs 7 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 56.72% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 56.72% YoY), while the FY2025 annual figure was $554000.0, down 90.19% from the prior year.
• Accounts Payables came in at $1.7 million for Q1 2026 at Acumen Pharmaceuticals, up from $554000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.6 million in Q4 2024 to a low of $554000.0 in Q4 2025.
• A 5-year average of $2.3 million and a median of $2.0 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 1050.79% in 2022 and tumbled 90.19% in 2025, its largest moves.
• Acumen Pharmaceuticals' Accounts Payables stood at $1.6 million in 2022, then slipped by 15.91% to $1.4 million in 2023, then surged by 309.57% to $5.6 million in 2024, then sank by 90.19% to $554000.0 in 2025, then soared by 198.74% to $1.7 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $1.7 million, $554000.0, and $682000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison